Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multicompartment Models: Overview01:14

Multicompartment Models: Overview

Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Clearance Models: Noncompartmental Models01:17

Clearance Models: Noncompartmental Models

Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving01:29

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving

Mechanistic models play a crucial role in algorithms for numerical problem-solving, particularly in nonlinear mixed effects modeling (NMEM). These models aim to minimize specific objective functions by evaluating various parameter estimates, leading to the development of systematic algorithms. In some cases, linearization techniques approximate the model using linear equations.
In individual population analyses, different algorithms are employed, such as Cauchy's method, which uses a...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The choice of time scales in survival analysis has implications: calendar time versus patients' time-to-event.

BMC medical research methodology·2026
Same author

Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation.

Frontiers in immunology·2026
Same author

The Challenge of Time-to-Event Analysis for Multiple Events: A Guided Tour From Time-to-First-Event to Recurrent Time-to-Event Analysis.

Biometrical journal. Biometrische Zeitschrift·2026
Same author

Response to van Rossum et al.: contextualizing ESOPEC in the evolving landscape of esophageal adenocarcinoma therapy.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.

Bone marrow transplantation·2025
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing risks and multistate models.

Claudia Schmoor1, Martin Schumacher, Jürgen Finke

  • 1Clinical Trials Unit, University Medical Center Freiburg, Freiburg, Germany. claudia.schmoor@uniklinik-freiburg.de

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 23, 2012
PubMed
Summary
This summary is machine-generated.

Hematopoietic stem-cell transplantation (HSCT) involves complex endpoints like graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). This report explains Cox-type models for analyzing these risks and survival in HSCT patients.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Related Experiment Videos

Last Updated: May 16, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Hematology
  • Clinical Trials
  • Biostatistics

Background:

  • Hematopoietic stem-cell transplantation (HSCT) presents complex clinical outcomes.
  • Key risks include graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM).
  • Standard survival analysis may not capture competing risks or sequential events.

Purpose of the Study:

  • To explain the use and interpretation of Cox-type regression models.
  • To address complex endpoints in HSCT studies, including competing risks and time-dependent events.
  • To guide analysis in randomized trials, specifically for GVHD prophylaxis.

Main Methods:

  • Discussion of composite endpoints (e.g., disease-free survival).
  • Explanation of competing risks models for events like GVHD.
  • Adaptation of multistate models for time under immunosuppressive therapy (IST).

Main Results:

  • Cox-type models offer flexibility for various HSCT endpoints.
  • Multistate models are crucial for understanding event dependencies (e.g., GVHD affecting relapse).
  • Appropriate modeling enhances the interpretation of treatment effects.

Conclusions:

  • Statistical modeling is essential for complex HSCT outcomes.
  • Cox-type and multistate models provide robust analytical frameworks.
  • Accurate analysis supports evidence-based clinical decision-making in HSCT.